| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Nodosin targets inflammatory pathways. It has been shown to alleviate ear swelling and reduce serum IL-2 levels. As a diterpenoid, it may modulate immune responses and inflammatory signaling pathways. Its mechanism of action makes it a valuable tool for studying inflammation and immune regulation.
|
|---|---|
| ln Vitro |
In vitro, nodosin has been studied for its anti-inflammatory effects. Its activity is concentration-dependent. In cell-based assays, nodosin reduces the production of inflammatory cytokines. Its anti-inflammatory activity makes it a valuable tool for studying inflammation and immune regulation.
|
| ln Vivo |
In vivo, nodosin alleviates ear swelling and reduces serum IL-2 levels in a xylene-induced mouse ear swelling model. Its anti-inflammatory effects support its potential for treating inflammatory conditions. However, detailed in vivo efficacy data and pharmacokinetic profiles are limited in publicly available sources.
|
| Enzyme Assay |
The in vitro anti-inflammatory assay for nodosin typically uses immune cells (e.g., macrophages) stimulated with inflammatory stimuli. Cells are treated with varying concentrations of the test compound (typically 0.1 to 100 µM). Cytokine production (IL-2, TNF-α, IL-6) is measured by ELISA.
|
| Cell Assay |
For in vitro cellular assays, immune cells are treated with nodosin at concentrations ranging from 0.1 to 100 µM for 1-24 hours. Cytokine production is measured by ELISA. Cell viability is assessed using MTT or CellTiter-Glo assays. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo efficacy studies, rodent models of inflammation (e.g., xylene-induced ear swelling) are used. Nodosin is administered orally or intraperitoneally at doses ranging from 1 to 50 mg/kg. Ear swelling is measured, and serum IL-2 levels are assessed by ELISA. All animal procedures are conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of nodosin have been partially characterized. The compound has a molecular weight of 362.42. Following oral administration, it shows moderate absorption.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology studies of nodosin are limited. In acute toxicity studies in rodents, the compound is tolerated at doses up to 50 mg/kg.
|
| References | |
| Additional Infomation |
Nodosin is a delta-lactone that functions as a metabolite. It has been reported to be found in Cephalotaxus japonicus, Cephalotaxus sinensis, and other organisms with relevant data.
Nodosin is a diterpenoid extracted from Isodon trichocarpus Kudo and I. Japonicus HARA. It has a molecular formula of C20H26O6 and a molecular weight of 362.42. It alleviates ear swelling and reduces serum IL-2 levels. It is not approved for human use and is intended for research purposes only. |
| Molecular Formula |
C20H26O6
|
|---|---|
| Molecular Weight |
362.41700
|
| Exact Mass |
362.172
|
| CAS # |
10391-09-0
|
| PubChem CID |
10248089
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
615.3±55.0 °C at 760 mmHg
|
| Flash Point |
222.1±25.0 °C
|
| Vapour Pressure |
0.0±4.0 mmHg at 25°C
|
| Index of Refraction |
1.602
|
| LogP |
-0.13
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
26
|
| Complexity |
728
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC1(CC[C@H]2[C@]3([C@@H]1[C@@H](OC3)O)[C@@H]4[C@@H](C[C@@H]5C[C@]4(C(=O)C5=C)C(=O)O2)O)C
|
| InChi Key |
WZYJEEIAFBHYJS-SONIPUFESA-N
|
| InChi Code |
InChI=1S/C20H26O6/c1-9-10-6-11(21)13-19(7-10,15(9)22)17(24)26-12-4-5-18(2,3)14-16(23)25-8-20(12,13)14/h10-14,16,21,23H,1,4-8H2,2-3H3/t10-,11-,12+,13-,14-,16-,19+,20+/m1/s1
|
| Chemical Name |
(1S,4S,8R,9R,12S,13S,14R,16S)-9,14-dihydroxy-7,7-dimethyl-17-methylidene-3,10-dioxapentacyclo[14.2.1.01,13.04,12.08,12]nonadecane-2,18-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~344.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7592 mL | 13.7961 mL | 27.5923 mL | |
| 5 mM | 0.5518 mL | 2.7592 mL | 5.5185 mL | |
| 10 mM | 0.2759 mL | 1.3796 mL | 2.7592 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
